What are biomarkers for aHUS?

Nov 25, 2008 ... Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2008;142(2): ... Feb 13, 2019 ... Eculizumab (Soliris®, Alexion Pharmaceuticals, Inc., New Haven, CT, USA) is a humanized chimeric monoclonal antibody consisting of a human ... For SOLIRIS® (eculizumab), see Medication Guide and get support. violator bookmark. WELCOME! You have been redirected to Ultomiris.com/gmg—ask your doctor if ... What side effects may I notice from receiving this medication? · Back pain · Cough · Diarrhea · Dizziness · Headache · Joint pain · Muscle pain · Nausea ... Eculizumab injection is used to treat a type of blood disease called paroxysmal nocturnal hemoglobinuria (PNH). Feb 22, 2023 ... This study demonstrates that the majority of patients benefit from eculizumab when adhering to the indications as formulated in the Dutch PNH guideline. 600mg weekly for the first 4 weeks, followed by 900mg for the fifth dose 1 week later, then 900mg every 2 weeks thereafter. Soliris 300 mg concentrate for solution for infusion. Active Ingredient: eculizumab. Company: Alexion Pharma UK Ltd. See contact details. Apr 3, 2025 ... Eculizumab (brand names Soliris, Bkemv, Epysqli) is used to treat paroxysmal nocturnal hemoglobinuria (PNH) in adults, and a rare chronic blood ... Jul 27, 2023 ... Soliris (eculizumab) has been approved in the European Union (EU) for expanded use to include the treatment of refractory generalised myasthenia ...